Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 707

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 707
---
 execution and delivery of this Agreement, Theo I SCSp, a special limited partnership ( société en commandite spéciale ) incorporated in the Grand Duchy of Luxembourg (“ Theo ”), SPAC and the Company have entered into a Backstop Agreement (in the form attached hereto as Exhibit E) (the “ Backstop Agreement ”) pursuant to which Theo, SPAC and the Company commit to cause that the Company and SPAC have a certain minimum amount of aggregate cash on the Closing Date, as set forth therein; WHEREAS, in connection with the Transactions, the Company and SPAC will exercise commercially reasonable efforts to enter into PIPE Subscription Agreements (as defined herein) with PIPE Investors (as defined herein) providing for investments in Company Shares at $10.00 per Company Share (the “ PIPE Investment ”); WHEREAS , at the Closing, SPAC, Sponsor, the Company, Parent, certain other shareholders of SPAC, certain shareholders of Parent, Theo, Centro de Diagnóstico Médico de Alta Complejidad, a sociedad anónima organized under the laws of Argentina (“ CIBIC ”), Bioceres S.A., a sociedad anónima organized under the laws of Argentina, the MultiplAI Shareholders and certain other Persons specified therein shall enter into a Registration Rights and Lock-up Agreement (substantially in the form attached hereto as Exhibit F) (the “ Registration Rights and Lock-up Agreement ”); and WHEREAS , at the Closing, the Company, SPAC and the warrant agent thereunder shall enter into an Assignment, Assumption and Amendment Agreement (in the form attached hereto as Exhibit G ) (the “ Assignment, Assumption and Amendment Agreement ”) pursuant to which, (i) SPAC will assign to the Company all of SPAC’s rights, interests, and obligations in and under the SPAC Warrant Agreement (as defined herein), and (ii) the SPAC Warrant Agreement will be amended to, inter alia , (a) change all references from “Warrants” (as such term is defined therein) to Company Warrants, (b) change all references from “Ordinary Shares” (as such term is defined therein) underlying such warrants to Company Shares, and (c) cause each outstanding Company Warrant to represent the right to acquire, from the date on which such Company Warrant becomes exercisable, one whole Company Share. NOW , THEREFORE , in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth